Independent review of trial event assessments by adjudication experts.
Proven expertise in delivering high-quality imaging data at a global scale.
With strengths in instrument engineering, signal processing, and pharmaceutical R&D, Perceptive Discovery consistently delivers successful imaging study designs and executions.
Effective RTSM, built on 30 years of experience, and connected to an ecosystem which includes eConsent and eCOA.
Highly established imaging centers for first-in-human and multicenter trials.
900+ agents radiolabeled and counting.
Supporting both malignant and non-malignant indications.
Experts in Alzheimer’s Disease, Parkinson’s Disease imaging and more.
Supporting over 85% of radiopharmaceutical companies.
Optimize preclinical and clinical trials in other areas and drug classifications.
Therapeutic and technical expertise in imaging modalities, protocol design, and acquisition.
Oncology imaging, RTSM, and clinical adjudication services.
Tackling unique rare disease trial supply, imaging and adjudication challenges.
Body composition imaging expertise you can rely on.
We are here to serve science.
From discovery, through early to late-phase clinical development, to regulatory approval and post-market, you can count on Perceptive to be dependable, diligent, and driven in everything we do.
Perceptive Discovery bridges preclinical insights to early clinical success, ensuring rigorous scientific analysis and high-quality data to support innovation.
Providing the right-fit randomization & trial supply management solution for your trials, delivered by experts.
The right people, experience, and technology to drive clinical trial imaging success.
Your one- stop shop, from radiolabeling and preclinical biodistribution studies to IND-enabling dosimetry and efficacy studies, Perceptive Discovery delivers precise, translatable multi-modality imaging data to accelerate your oncology and radiopharmaceutical programs.
Perceptive Discovery delivers advanced preclinical oncology imaging and radiopharmaceutical development services to support therapeutic programs from discovery through early clinical development. Our cross-disciplinary team of radiochemists, imaging scientists, and oncology pharmacologists, work collaboratively to de-risk discovery and early-phase development by visualizing images of anti-tumor efficacy, target engagement, pharmacokinetics, dosimetry and therapeutic biodistribution in clinically relevant tumor models.
With deep expertise in radiopharmaceuticals and radioligand therapy (RLT), we help clients design and validate custom-labeled agents, quantify tumor uptake, and predict human dose and safety profiles—accelerating the path from concept to clinic.
Support your RLT program with comprehensive imaging and dosimetry services. We design studies using diagnostic/therapeutic isotope pairs (e.g., Zr-89/Lu-177 or Pb-203/Pb-212) to evaluate biodistribution, tumor targeting, and normal tissue dose.
Design and validate companion imaging agents for patient stratification and dose prediction using isotopes like F-18, Ga-68, Cu-64, and Zr-89.
Visualize CAR-T, oncolytic virus, and engineered cell biodistribution in real time using bioluminescence and advanced radiolabeling.
Quantify efficacy in disease-relevant models to increase translational confidence and guide candidate selection.
Gain fast, actionable insights through automated data processing pipelines—supporting segmentation, dosimetry, PK/PD evaluation, and therapeutic response modeling.
Reach out today and one of our solution experts will be in touch to learn about your specific needs.
"*" indicates required fields
Δ
Let’s design the right imaging strategy to get you there.
